Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering
A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.
Source: medscape.com
Stay updated with breaking news from Abbott Diagnostic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.
Infectious Disease Diagnostics Market Forecasts to 2028 – Global Analysis By Technique (Traditional, Molecular), End User (Hospitals & Clinics, Diagnostic